BMS-986004 + Sirolimus + Tacrolimus
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graft-versus-host-disease
Conditions
Graft-versus-host-disease, GVHD, GVHD, Acute
Trial Timeline
Feb 15, 2019 → Jul 25, 2023
NCT ID
NCT03605927About BMS-986004 + Sirolimus + Tacrolimus
BMS-986004 + Sirolimus + Tacrolimus is a phase 1 stage product being developed by Bristol Myers Squibb for Graft-versus-host-disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03605927. Target conditions include Graft-versus-host-disease, GVHD, GVHD, Acute.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03605927 | Phase 1 | Completed |
Competing Products
13 competing products in Graft-versus-host-disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 33 |
| Belumosudil (KD025) | Sanofi | Phase 2 | 51 |
| Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QD | Sanofi | Phase 2 | 51 |
| INCA034176 | Incyte | Phase 1/2 | 38 |
| INCA034176 + Best Available Therapy (BAT) | Incyte | Phase 3 | 74 |
| INCA034176 | Incyte | Phase 3 | 74 |
| Itacitinib | Incyte | Phase 2 | 49 |
| INCA034176 + Placebo + Corticosteroids | Incyte | Phase 3 | 74 |
| Itacitinib | Incyte | Phase 2 | 49 |
| INCA034176 + Best available Treatment (BAT) | Incyte | Phase 2 | 49 |
| Axatilimab + Ruxolitinib + Corticosteroids | Incyte | Phase 2 | 49 |
| axatilimab | Syndax Pharmaceuticals | Phase 1/2 | 36 |
| Axatilimab | Syndax Pharmaceuticals | Phase 2 | 47 |